未登录

A

Anzhelika Vorobyeva

department of immunology

H指数:22

被引数:1,381

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Imaging of ROR1 expression in tumors using radiolabeled affibody molecules

使用放射性标记的亲和体分子对肿瘤中ROR1表达进行成像

European Journal of Nuclear Medicine and Molecular Imaging

IF7.6

2026-08-010

OA

Affibody-Derived Drug Conjugates Targeting The Epidermal Growth Factor Receptor Are Potent And Specific Cytotoxic Agents

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE

IF3.7

2025-10-010

PRE

Selection of the optimal chelator for labeling of DARPin Ec1 with gallium-68 for PET imaging of EpCAM expression

用于EpCAM表达PET成像的DARPin Ec1与镓-68标记的最佳螯合剂选择

EJNMMI Radiopharmacy and Chemistry

IF3.3

2025-05-300

OAAI

Impact of Radiometal Chelates on In Vivo Visualization of Immune Checkpoint Protein Using Radiolabeled Affibody Molecules

放射性金属螯合物对使用放射性标记Affibody分子进行免疫检查点蛋白体内可视化的影响

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE

IF3.7

2025-02-190

OA

Evaluation of a novel 177Lu-labelled therapeutic Affibody molecule with a deimmunized ABD domain and improved biodistribution profile

评估具有脱敏ABD结构域和改善的生物分布特征的新型177lu-标记的治疗性亲和体分子

European Journal of Nuclear Medicine and Molecular Imaging

IF7.6

2024-07-150

OAAI

Reduction of renal activity retention of radiolabeled albumin binding domain-derived affinity proteins using a non-residualizing label strategy compared with a cleavable glycine-leucine-glycine-lysine-linker

MOLECULAR MEDICINE REPORTS

IF3.5

2023-12-280

OAAI

Conditionally activated affibody-based prodrug targeting EGFR demonstrates improved tumour selectivity

JOURNAL OF CONTROLLED RELEASE

IF11.5

2023-05-012

OAAI

Comparison of HER2-targeted affibody conjugates loaded with auristatin-and maytansine-derived drugs

JOURNAL OF CONTROLLED RELEASE

IF11.5

2023-03-016

OAAI

Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis

IF5.5

2022-11-194

OAAI

Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart

IF5.5

2022-08-024

OAAI

Preclinical Evaluation of a New Format of 68Ga- and 111In-Labeled Affibody Molecule ZIGF-1R:4551 for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT

IF5.5

2022-07-157

OAAI

Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules

IF3.9

2022-05-316

OAAI

Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule 188Re-ZHER2:41071

IF5.5

2022-05-208

OAAI

Epithelial cell adhesion molecule-targeting designed ankyrin repeat protein-toxin fusion Ec1-LoPE exhibits potent cytotoxic action in prostate cancer cells

ONCOLOGY REPORTS

IF3.9

2022-03-185

OAAI

Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2

IF5.5

2022-02-264

OAAI

The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy

IF5.5

2021-11-2110

OAAI

Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein

IF5.5

2021-11-036

OAAI

Affibody-Mediated PNA-Based Pretargeted Cotreatment Improves Survival of Trastuzumab-Treated Mice Bearing HER2-Expressing Xenografts

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2021-10-2810

OA

Phase I Trial of 99mTc-(HE)3-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2021-08-1239

OAAI

Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody(R) Molecules 177Lu-ABY-271 and 177Lu-ABY-027: Impact of DOTA Position on ABD Domain

IF5.5

2021-06-0712

OAAI